Related Experiment Video
Updated: Feb 28, 2026

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
Identification of gene markers associated with metastasis in clear cell renal cell carcinoma
Hailing Yang1, Pengfei Huo2, Guozhang Hu1
1Emergency Department, China-Japan Union Hospital, Jilin University, Changchun, Jilin 130033, P.R. China.
Abstract:
The present study aimed to screen potential target genes for the early diagnosis and treatment of early metastatic clear cell renal cell carcinoma (ccRCC) using the microarray data of early metastatic and non-metastatic ccRCC samples. The DNA microarray dataset GSE47352 was downloaded from Gene Expression Omnibus and included 4 early metastatic and 5 non-metastatic ccRCC samples. Differentially expressed genes (DEGs) were screened using the limma package. Then, pheatmap package was used to conduct two-way clustering for the DEGs. Subsequently, MAPPFinder and GenMAPP were employed separately to perform functional and pathway enrichment analysis for the DEGs. Additionally, a protein-protein interaction (PPI) network was constructed using Cytoscape, and small drug molecules were searched using Connectivity map (cmap). In total, 196 upregulated and 163 downregulated genes were identified. DEGs, including JUN, tumor necrosis factor (TNF), Ras homolog family member B (RHOB) and transforming growth factor β2 (TGFβ2) were significantly enriched in the signaling pathway of renal cell carcinoma. Furthermore, nuclear receptor subfamily 4 group A member 1 (NR4A1) was significantly enriched in the mitogen-activated protein kinase signaling pathway; in addition, laminin subunit α (LAMA) 1, LAMA2 and LAMA4 were significantly enriched in extracellular matrix-receptor interaction. JUN (degree=6) had the highest degree in the PPI network. Thapsigargin (score=-0.913) possessed the highest performance in terms of the treatment of early metastatic ccRCC. In the present study, it was discovered that certain DEGs, including JUN, TNF, RHOB, NR4A1, TGFβ2, LAMA1, LAMA2 and LAMA4 were potential target genes associated with early metastatic ccRCC. In addition, thapsigargin could be used as an efficient small drug molecule for the treatment of early metastatic ccRCC.
Insights
This study identified key genes like JUN and TNF for early metastatic clear cell renal cell carcinoma (ccRCC) diagnosis and treatment. Thapsigargin shows promise as an effective drug for early metastatic ccRCC.
Area of Science:
- Oncology
- Genomics
- Bioinformatics
Background:
- Early detection and treatment of metastatic clear cell renal cell carcinoma (ccRCC) are critical.
- Identifying specific molecular targets is essential for improving patient outcomes.
Purpose of the Study:
- To screen for potential target genes for early diagnosis and treatment of metastatic ccRCC.
- To identify novel therapeutic strategies for early metastatic ccRCC.
Main Methods:
- Utilized microarray data (GSE47352) from metastatic and non-metastatic ccRCC samples.
- Applied differential gene expression analysis, pathway enrichment, and protein-protein interaction network construction.
- Screened for potential small molecule drugs using the Connectivity Map (cmap).
Main Results:
- Identified 196 upregulated and 163 downregulated differentially expressed genes (DEGs).
- Key DEGs (JUN, TNF, RHOB, TGFβ2, NR4A1, LAMA1, LAMA2, LAMA4) were linked to ccRCC signaling pathways.
- JUN exhibited the highest connectivity in the protein-protein interaction network.
- Thapsigargin demonstrated significant potential for treating early metastatic ccRCC.
Conclusions:
- JUN, TNF, RHOB, NR4A1, TGFβ2, LAMA1, LAMA2, and LAMA4 are potential diagnostic and therapeutic targets for early metastatic ccRCC.
- Thapsigargin is a promising small molecule drug candidate for early metastatic ccRCC treatment.

